A Phase 3 clinical trial involving semaglutide changed status on September 25, 2026. The study, registered as NCT06738979 and titled "A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects," is listed as completed.
According to the trial record, the study was designed to compare a semaglutide injection product against Wegovy in obese subjects for weight management. The registry entry lists the phase as Phase 3 and the current status as completed.
No results, outcomes, or efficacy data are included in this update. The completion status reflects the trial's progression stage as recorded on ClinicalTrials.gov, not a summary of findings. Any results, if and when posted, would appear as a separate update to the same registry entry.
Semaglutide is an approved compound, and Wegovy is one of its marketed formulations referenced in this comparative study. This brief reports only the status change as listed in the trial record and does not characterize the comparative performance of either product.
Readers interested in background on this compound can consult the semaglutide overview for additional context.